What this Trial Is About

Researchers are evaluating the benefit of implanting an implantable cardioverter defibrillator (ICD) in patients with coronary artery disease who have survived cardiac arrest caused by ventricular fibrillation or sustained ventricular tachycardia. These patients have undergone revascularization procedures and have a left ventricular ejection fraction (LVEF) above 35%. The study aims to assess whether ICD implantation improves outcomes in this specific group. Participants are randomly assigned to receive ICD implantation as a device-based secondary prevention measure. The study includes patients who had complete revascularization through procedures such as PCI, CABG, or hybrid coronary revascularization before receiving the ICD. The study is designed to compare outcomes between those who receive the ICD and those who do not, focusing on long-term effects. During the study, participants are monitored for all-cause mortality over a 5-year period. Researchers will track survival rates and assess the overall benefit of ICD implantation in this patient population. The study involves follow-up assessments to evaluate health status and any adverse events, ensuring comprehensive safety monitoring throughout the participation period.

A Danish ICD-study in Patients with Coronary Artery Disease Resuscitated from Ventricular Fibrillation